Molbio Diagnostics Ltd.'s initial public offering (IPO) has been subscribed 4.39 times as of the third day of bidding, August 12, according to livemint.com. The IPO opened on August 10 and is set to close today, marking the final day for investors to place bids. The grey market premium for the shares stands at around ₹138 per share, indicating strong investor interest.
The IPO subscription covers all categories of investors, reflecting broad-based demand for the molecular diagnostics firm's shares. Molbio Diagnostics, established in October 2000, develops, manufactures, and commercializes rapid diagnostic solutions globally. The company’s mainboard IPO has attracted significant attention since the bidding began, with the current subscription rate underscoring robust market appetite.
The strong subscription rate positions Molbio Diagnostics among notable recent IPOs in the healthcare diagnostics sector in India. The firm operates in a growing market for rapid diagnostic technologies, which has seen increased investor focus amid rising healthcare awareness. The ₹138 grey market premium signals positive sentiment and potential for the stock upon listing, aligning with trends seen in comparable healthcare IPOs.
The IPO closes on August 12, after which the company will finalize allotments and proceed with listing formalities. Investors will learn the final subscription details and allotment status following the close of the offer, as disclosed by the company and market regulators.